Monday September 17, 2018 0 comments
The Fort Collins company focuses on developing targeted cancer treatments through the commercialization of largazole analogs by inhibiting histone deacetylases (HDACs).
Colorado BioScience Association Vice President Jennifer Jones presented the $7,500 award to Cetya Therapeutics CEO Cliff Hendrick. The award was sponsored by Dorsey & Whitney and EKS&H Capital Advisors.
“The venture showcase wrapped up a high-energy day highlighting the global impact our innovators from Colorado make,” said Jones.
“Congratulations to Cetya Therapeutics and our other venture showcase finalists, Brava Diagnostics and Veloce Corporation.”
“Our team is energized to be named winner of the Colorado Life Science Innovation Forum Venture showcase,” said Cetya’s Hendrick.
“The recognition gives our company additional momentum as we advance our oncology program.”
Colorado BioScience Association welcomed national thought leaders and local executives throughout the day with conversations on reshaping research funding, the emergence of artificial intelligence in healthcare, value-based partnerships, changing patient and provider behaviors, partnership with leading business development executives and the future of immunotherapy.
Sponsors of this year’s awards included Fitzsimons, Biotechnology Industry Association, EY and CU BioFrontiers Institute.